Su X-L, Wang S-H, Komal S, Cui L-G, Ni R-C, Zhang L-R, et al
A 2023 Phase 2 clinical study on retatrutide published in the New England Journal of Medicine demonstrated significant reductions in body weight in research participants, underscoring its importance as a research compound
Risk factors and emerging therapies in amyotrophic lateral sclerosis
In their announcement about the retatrutide study, Eli Lilly medical experts said that about 11% of study volunteers who received the highest dose of the drug stopped taking it and dropped out of the study due to unpleasant side effects
and the pathways differing between the FI group and the GSH group were Autophagy-other, Autophagy-animal, and Autophagy-animal, Glycosylphosphatidylinositol (GPI)-anchor biosynthesis, Glycerophospholipid metabolism